11 May 2016
What do you get from your subscription?
10 year forecasts
View Datamonitor Healthcare’s 10-year patient based forecasts for key metabolic indications, including the impact of late-stage pipeline drugs such as Aprela for menopausal symptoms
Understand the unmet needs for type 2 diabetes and other key metabolic diseases to identify growth opportunities in your market
Examine patient populations, 10 year incident case forecasts and patient segments to recognize market potential for the diabetes, dyslipidemia, obesity and osteoporosis markets
Pipeline and marketed drugs
Assess the insulin pipeline, marketed drugs for non-insulin antidiabetics and compare clinical and commercial drug attributes to determine the route you should take to market